Ensysce Biosciences (ENSC) vs Vistagen Therapeutics (VTGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vistagen Therapeutics is the larger company by market cap ($10.5 million vs $10.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENSC | VTGN |
|---|---|---|
| Share price | $0.527 | $0.2361 |
| Market cap | $10.25M | $10.48M |
| 1-day change | +15.07% | -4.10% |
| YTD return | — | -62.70% |
| 1-year return | — | -93.88% |
| 5-year return | — | -99.66% |
| EPS (TTM) | $-2.47 | $-1.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.75 | $5.14 |
| 52-week low | $0.23 | $0.20 |
| Distance from 52-week high | -80.84% | -95.41% |
| Analyst consensus | none | none |
| Avg. price target upside | +1465.46% | +323.55% |
| Average volume | 14.21M | 12.36M |
| Shares outstanding | 19.46M | 44.38M |
| Employees | 8 | 41 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ensysce Biosciences
ENSC stock →Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Vistagen Therapeutics
VTGN stock →Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
ENSC vs VTGN FAQ
Which is bigger, Ensysce Biosciences or Vistagen Therapeutics?
Vistagen Therapeutics (VTGN) is larger, with a market capitalization of $10.48M compared with $10.25M for Ensysce Biosciences (ENSC).
Are Ensysce Biosciences and Vistagen Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.